Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Inclusion criteria

• Aged 18-75 years, regardless of gender.
• Diagnosed with HCC either by histopathological and/or cytological examination meeting pathological diagnostic criteria, or in line with the clinical diagnostic criteria of the aforementioned guidelines.
• Unresectable or metastatic HCC, and have experienced treatment failure with targeted drugs and immune checkpoint inhibitors.
• Child-Pugh liver function score: Class A/B (≤7 points).
• Expected survival time ≥ 3 months.
• ECOG performance status 0 or 1.
• Barcelona Clinic Liver Cancer (BCLC) stage B or C.
• No severe involvement of the portal vein, and no invasion of the hepatic vein, superior vena cava, or inferior vena cava.

Exclusion criteria

• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
• Previous history of liver or other organ transplantation.
• Has participated in another clinical study within 4 weeks prior to the first dose.
• Has a known history of, or any evidence of CNS metastases.
• Clinically symptomatic or recurrently drained pleural effusion, pericardial effusion, or ascites.
• History of bleeding event due to esophageal and/or gastric varices within 3 months prior to the first dose of study treatment.